Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr1.58 SEK
Change Today +0.03 / 1.94%
Volume 3.2M
KARO On Other Exchanges
Symbol
Exchange
OTC US
Stockholm
Frankfurt
As of 11:29 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

karo bio ab (KARO) Snapshot

Open
kr1.57
Previous Close
kr1.55
Day High
kr1.59
Day Low
kr1.55
52 Week High
03/19/15 - kr1.77
52 Week Low
12/17/14 - kr0.51
Market Cap
1.5B
Average Volume 10 Days
10.2M
EPS TTM
kr-0.08
Shares Outstanding
939.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KARO BIO AB (KARO)

Related News

No related news articles were found.

karo bio ab (KARO) Related Businessweek News

No Related Businessweek News Found

karo bio ab (KARO) Details

Karo Bio AB (publ) operates as a research and development company that specialized in nuclear receptors as target proteins for the development of new drugs primarily in Sweden. The company is involved in the preclinical drug development projects in the areas of inflammatory conditions, autoimmune diseases, and cancer. Its pipeline products include nuclear receptor that regulates various functions in the body affecting a range of diseases, such as dyslipidemia, diabetes, obesity, inflammation, and osteoporosis, and certain forms of cancer; estrogen receptor beta that regulates various functions in the body; and RORgamma for the treatment of autoimmune diseases, such as rheumatoid arthritis, ulcerative colitis, and multiple sclerosis. The company has collaboration agreements with Pfizer Inc. to discover and develop compounds for the treatment of autoimmune diseases. Karo Bio AB (publ) was founded in 1987 and is headquartered in Huddinge, Sweden.

24 Employees
Last Reported Date: 04/8/15
Founded in 1987

karo bio ab (KARO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

karo bio ab (KARO) Key Developments

Karo Bio Announces Consolidated and Parent Earnings Results for the Second Quarter and First Half Year Ended June 30, 2015

Karo Bio announced consolidated and parent earnings results for the second quarter and first half year ended June 30, 2015. For the quarter, on consolidated basis, the company reported net sales of SEK 1,833,000 against SEK 6,825,000 a year ago. Operating loss was SEK 21,546,000 against SEK 14,291,000 a year ago. Loss after financial items was SEK 21,545,000 against SEK 14,215,000 a year ago. Net loss for the period attributable to shareholders of the parent company was SEK 21,545,000 against SEK 14,215,000 a year ago. Loss per share was SEK 0.03 against SEK 0.02 a year ago. Cash flow used in operating activities was SEK 12,976,000 against SEK 13,145,000 a year ago. For the half year, on consolidated basis, the company reported net sales of SEK 2,258,000 against SEK 13,185,000 a year ago. Operating loss was SEK 36,899,000 against SEK 27,689,000 a year ago. Loss after financial items was SEK 36,890,000 against SEK 27,593,000 a year ago. Net loss for the period attributable to shareholders of the parent company was SEK 36,890,000 against SEK 27,593,000 a year ago. Loss per share was SEK 0.04 against SEK 0.09 a year ago. Cash flow used in operating activities was SEK 32,364,000 against SEK 26,282,000 a year ago. For the quarter, on parent basis, the company reported net sales of SEK 1,833,000 against SEK 6,825,000 a year ago. Operating loss was SEK 21,503,000 against SEK 14,306,000 a year ago. Loss after financial items was SEK 21,500,000 against SEK 14,228,000 a year ago. Net loss for the period attributable to shareholders of the parent company was SEK 21,500,000 against SEK 14,228,000 a year ago. For the half year, on parent basis, the company reported net sales of SEK 2,258,000 against SEK 13,185,000 a year ago. Operating loss was SEK 36,856,000 against SEK 27,704,000 a year ago. Loss after financial items was SEK 36,844,000 against SEK 27,603,000 a year ago. Net loss for the period attributable to shareholders of the parent company was SEK 36,844,000 against SEK 27,603,000 a year ago.

Karo Bio Aktiebolag (publ), Q2 2015 Earnings Call, Jul 10, 2015

Karo Bio Aktiebolag (publ), Q2 2015 Earnings Call, Jul 10, 2015

Karo Bio AB Announces Earnings Results for the First Quarter Ended March 31, 2015

Karo Bio AB announced earnings results for the first quarter ended March 31, 2015. The company reported that net loss attributable to shareholders in the parent company for the first quarter ended March 31, 2015 was SEK 15.34 million, or SEK 0.02 loss per share, compared to a net loss attributable to shareholders in the parent company of SEK 13.38 million, or SEK 0.02 loss per share, for the same quarter ended March 31, 2014. Net sales for the first quarter ended March 31, 2015 were SEK 425,000, compared to SEK 6.36 million for the same quarter ended March 31, 2014. Operating loss for the first quarter ended March 31, 2015 was SEK 15.35 million, compared to an operating loss of SEK 13.4 million for the same quarter ended March 31, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KARO:SS kr1.58 SEK +0.03

KARO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KARO.
View Industry Companies
 

Industry Analysis

KARO

Industry Average

Valuation KARO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 54.7x
Price/Book 43.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 73.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KARO BIO AB, please visit www.karobio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.